EUROFINS SCIENT (ERFSF)
(Delayed Data from OTC)
$59.27 USD
+0.09 (0.15%)
Updated Sep 6, 2024 10:50 AM ET
2-Buy of 5 2
B Value B Growth C Momentum B VGM
Income Statements
Fiscal Year end for EUROFINS SCIENT falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 7,051 | 7,072 | 7,948 | 6,213 | 5,110 |
Cost Of Goods | 5,715 | 5,581 | 5,771 | 4,670 | 4,177 |
Gross Profit | 1,336 | 1,491 | 2,177 | 1,543 | 933 |
Selling & Adminstrative & Depr. & Amort Expenses | 785 | 677 | 691 | 632 | 528 |
Income After Depreciation & Amortization | 551 | 814 | 1,486 | 911 | 405 |
Non-Operating Income | -2 | 150 | 2 | 2 | 1 |
Interest Expense | 140 | 147 | 243 | 126 | 113 |
Pretax Income | 458 | 822 | 1,250 | 793 | 304 |
Income Taxes | 125 | 184 | 324 | 176 | 85 |
Minority Interest | -3 | -5 | 0 | 1 | 0 |
Investment Gains/Losses | NA | 0 | 0 | 0 | 0 |
Other Income/Charges | NA | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 333 | 638 | 926 | 617 | 219 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 336 | 643 | 926 | 616 | 219 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 1,162 | 1,345 | 2,019 | 1,398 | 848 |
Depreciation & Amortization (Cash Flow) | 612 | 531 | 533 | 487 | 443 |
Income After Depreciation & Amortization | 551 | 814 | 1,486 | 911 | 405 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 198.00 | 199.00 | 200.60 | 195.90 | 178.00 |
Diluted EPS Before Non-Recurring Items | 2.89 | 3.64 | 5.96 | 3.95 | 2.26 |
Diluted Net EPS (GAAP) | 1.70 | 3.23 | 4.61 | 3.14 | 1.17 |
Fiscal Year end for EUROFINS SCIENT falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | NA | NA | NA | NA |
Cost Of Goods | NA | NA | NA | NA | NA |
Gross Profit | NA | NA | NA | NA | NA |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Non-Operating Income | NA | NA | NA | NA | NA |
Interest Expense | NA | NA | NA | NA | NA |
Pretax Income | NA | NA | NA | NA | NA |
Income Taxes | NA | NA | NA | NA | NA |
Minority Interest | NA | NA | NA | NA | NA |
Investment Gains/Losses | NA | NA | NA | NA | NA |
Other Income/Charges | NA | NA | NA | NA | NA |
Income From Cont. Operations | NA | NA | NA | NA | NA |
Extras & Discontinued Operations | NA | NA | NA | NA | NA |
Net Income (GAAP) | NA | NA | NA | NA | NA |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | NA | NA | NA | NA |
Diluted EPS Before Non-Recurring Items | NA | NA | NA | NA | NA |
Diluted Net EPS (GAAP) | NA | NA | NA | NA | NA |